![Immatics N.V. logo](/logos/IMTX.webp)
Immatics N.V.
NASDAQ:IMTX
Overview | Financials
Company Name | Immatics N.V. |
Symbol | IMTX |
Currency | USD |
Price | 11.73 |
Market Cap | 1,208,811,690 |
Dividend Yield | 0% |
52-week-range | 7.15 - 13.77 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Harpreet Singh Ph.D. |
Website | https://www.immatics.com |
An error occurred while fetching data.
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD